Cole and Jaenisch dig into AI poisoning in pharma manufacturing, how it hides in plain sight, and who should be accountable for catching it.
|Articles|April 22, 2020
Syntegon Pharma Technology, Inc.
Author(s)Syntegon Pharma Technology, Inc.
Syntegon Pharma Technology, Inc., formerly Bosch Packaging Technology, is your single- source supplier of process technology and packaging solutions for the pharmaceutical industry.
Syntegon Pharma Technology, Inc., formerly Bosch Packaging Technology, is your single- source supplier of process technology and packaging solutions for the pharmaceutical industry. The portfolio includes single units, complete lines, and integrated systems for the manufacturing and processing of liquid and solid pharmaceuticals.
INTERPHEX Booth # 3305
Syntegon Pharma Technology, Inc.
8700 Wyoming Ave N, Minneapolis, MN 55445
tel. 763.424.4700
Related to this article
Mahmood Majeed, ZS, explains why measurable AI outcomes in pharma supply chain and manufacturing jumped from 29% to 53%, and how GMP limits and GxP validation shape adoption.
BMS-Tempus, Roche-Zymeworks, and LGM-Sannova deals show what AI data, trispecifics, and nitrosamine testing mean for CMC, QA, and development teams.
Univar Solutions scientists developed a lidocaine cream built on starch, sorbitol, coconut oil, and beeswax that matched a commercial benchmark on viscosity, assay, and hydration.
Nate Edwards of Arya Consulting moderates a discussion with Elisabeth Gardiner of Tevard Biosciences and Donny Xu of the RTW Institute about the regulatory and manufacturing hurdles facing rare disease drug developers.
FDA grants ravulizumab accelerated approval in IgA nephropathy after a 43.4% proteinuria cut, signaling new IV biologic demand for drug manufacturers.
Jane Zhang of ETCH Sourcing explains why geopolitics, transparency, and partnership now weigh as heavily as cost and quality when companies choose suppliers, in this episode of Ask the Expert, moderated by Susan J. Schniepp of Nelson Labs.
FDA approves GSK's bepirovirsen for chronic hepatitis B after a 19% functional cure rate, raising oligonucleotide scale-up stakes for manufacturers.
Trending on Pharmaceutical Technology
1
Formulation and Evaluation of a Sustainable Analgesic Cream Utilizing Renewable Bio-Based Ingredients and Green Chemistry Design Principles
2
Nitrosamine Problems and Industry Solutions: PharmTech Explained
3
OpenAI Bets on Accelerating Drug Development Timelines With Orchestra Bio
4
Germany’s Medical Biotechnology Sector is Flourishing
5